Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathways

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Xiong, Xuan ^a   Mei, Wenjuan ^a   Xie, Yanyun ^a,b   Liu, Jishi ^c   Lu, Miaomiao ^a   Peng, Xiongqun ^a   Yang, Congyin ^a   Zhang, Xin ^a   Xie, Mingyan ^a   Luo, Renna ^a   Yuan, Xiangning ^a   Huang, Ling ^a   Wu, Lin ^a   Qin, Jiao ^a   Peng, Yu ^a   Jia, Xiujie ^d   Hu, Gaoyun ^e   Tang, Damu ^b   Tao, Lijian ^a,f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b MCMASTER UNIVERSITY   (Canada)

^c THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e School of Pharmaceutical Sciences   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; FLUOROFENIDONE; GLUCOSE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PLASMA PROTEIN; PROTEIN KINASE B; PROTEIN KINASE C ZETA; PROTEIN P22; PYRIDONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 5-METHYL-1-(3-FLUOROPHENYL)-2-(1H)-PYRIDONE; GLUCOSE BLOOD LEVEL; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG ACTIVITY; EARLY INTERVENTION; ENZYME ACTIVATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; KIDNEY FUNCTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; ANIMAL; BLOOD; DIABETIC NEUROPATHIES; DRUG EFFECTS; KIDNEY; METABOLISM;

ANIMALS; BLOOD GLUCOSE; BLOOD PROTEINS; CHOLESTEROL; DIABETIC NEUROPATHIES; KIDNEY; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NADPH OXIDASE; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908637490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111242     Document Type: Article

References (42)

1. Stitt-Cavanagh E, MacLeod L, Kennedy C (2009) The podocyte in diabetic kidney disease. ScientificWorldJourna 9: 1127-39.
2. Lin X, Tao L, Tang D (2013) Gene therapy, a targeted treatment for diabetic nephropathy. Curr Med Chem. 20: 3774-84.
3. Balakumar P, Arora MK, Reddy J, Anand-Srivastava MB (2009) Pathophys-iology of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol. 54: 129-38.
4. Leiter LA (2005) The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract. 68 Suppl 2: S3-14.
5. Forbes JM, Thallas V, Thomas M.C., Founds HW, Burns WC, et al. (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17: 1762-4.
6. Danesh FR, Sadeghi MM, Amro N, Philips C., Zeng L, et al. (2002) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA. 99: 8301-5.
7. Lewis EJ, Lewis JB (2003) Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol. 7: 1-8.
8. Remuzzi G, Ruggenenti P, Perna A., Dimitrov BD, de Zeeuw D, et al. (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 15: 3117-25
9. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, et al. (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 351: 1941-51.
10. Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 74: 22-36.
11. th Ed. 1777-1818.
12. Alsaad KO, Herzenberg AM (2007) Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol. 60: 18-26.
13. Quaggin SE, Coffman TM (2008) Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? J Am Soc Nephrol. 18: 364-6.
14. Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA. 97: 7667-9.
15. Peng ZZ, Hu GY, Shen H, Wang L., Ning WB, et al. (2009) Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology 14: 565-72.
16. Wang LH, Liu JS, Ning W.B., Yuan QJ, Zhang FF, et al. (2011) Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. Pharmacology 88: 88-99.
17. Wang L, Hu GY, Shen H, Peng Z.Z., Ning WB, et al. (2009) Fluorofenidone inhibits TGF-beta1 induced CTGF via MAPK pathways in mouse mesangial cells. Pharmazie 64: 680-4.
18. Xia L, Wang H, Munk S., Frecker H, Goldberg HJ, et al. (2007) Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am J Physiol Endocrinol Metab. 293: E1280-8.
19. Xia L, Wang H, Munk S., Kwan J, Goldberg HJ, et al. (2008) High glucose activates PKC-zeta and NADPH oxidase through autocrine TGF-beta1 signaling in mesangial cells. Am J Physiol Renal Physiol. 295: F1705-14.
20. Wu D, Peng F, Zhang B., Ingram AJ, Kelly DJ, et al (2009) PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol. 20: 554-66.
21. Susztak K, Böttinger E, Novetsky A., Liang D, Zhu Y, et al. (2004) Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53: 784-94.
22. Nicholas SB, Liu J, Kim J., Ren Y, Collins AR, et al. (2010) Critical role for osteopontin in diabetic nephropathy. Kidney Int. 77: 588-600.
23. Gartner K (1978). Glomerular hyperfiltration during the onset of dia-betes mellitus in two strains of diabetic mice (C57BL/6J db/db and C57BL/KsJ db/db). Diabetologia 15: 59-63.
24. Ziyadeh F, Hoffman B, Han D., Iglesias-de la Cruz MC, Hong SW, et al. (2000) Long-term prevention of renal insuf ficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020.
25. Cohen MP, Lautenslager GT, Shearman CT (2001) Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism 50: 1435-1440.
26. Pan D, Zhang D, Wu J., Chen C, Xu Z, et al. (2014) A novel proteoglycan from Ganoderma lucidum fruiting bodies protects kidney function and ameliorates diabetic nephropathy via its antioxidant activity in C57BL/6 db/db mice. Food Chem Toxicol. 63: 111-8.
27. Ma KL, Zhang Y, Liu J., Wu Y, Hu ZB, et al. (2014) Establishment of an inflamed animal model of diabetic nephropathy. Int J Biol Sci. 10: 149-59.
28. Chiarelli F, Gaspari S, Marcovecchio ML (2009) Role of growth factors in diabetic kidney disease. Horm Metab Res. 41: 585-93.
29. Fujita H, Omori S, Ishikura K., Hida M, Awazu M (2004) ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol. 286: F120-6.
30. Ha TS (2010) High-glucose and advanced glycosylation end products increased podocyte permeability via PI3-K/Akt signaling. J Mol Med (Berl). 88: 391-400.
31. Sharma K, Ix JH, Mathew A.V., Cho M., Pflueger A, et al. (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 22: 1144-51.
32. Levin A, Beaulieu MC (2011) Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. J Am Soc Nephrol. 22: 992-3.
33. Tanios BY, Ziyadeh FN (2012) Emerging therapies for diabetic nephropathy patients: beyond blockade of the Renin-Angiotensin system. Nephron Extra. 2: 278-82.
34. Gilbert RE, Zhang Y, Williams S.J., Zammit SC, Stapleton DI, et al. (2012) A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One 7(10): e47160.
35. RamachandraRao SP, Zhu Y, Ravasi T., McGowan TA, Toh I, et al. (2009) Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 20: 1765-75.
36. Zeng R, Xiong Y, Zhu F., Ma Z, Liao W, et al. (2013) Fenofibrate attenuated glucose-induced mesangial cells proliferation and extracellular matrix synthesis via PI3K/AKT and ERK1/2. PLoS One 8(10): e76836.
37. Hudkins KL, Pichaiwong W, Wietecha T., Kowalewska J, Banas MC, et al. (2010) BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol. 21: 1533-42.
38. Pichaiwong W, Hudkins KL, Wietecha T, Nguyen T.Q., Tachaudomdach C., et al. (2013) Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 24: 1088-102.
39. Taye A, Abouzied MM, Mohafez OM (2013) Tempol ameliorates cardiac fibrosis in streptozotocin-induced diabetic rats: role of oxidative stress in diabetic cardiomyopathy. Naunyn Schmiedebergs Arch Pharmacol. 386: 1071-80.
40. Shimizu F, Sano Y, Haruki H., Kanda T (2011) Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-b and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 54: 1517-26.
41. Kwon DS, Kwon CH, Kim J.H., Woo JS, Jung JS, et al. (2006) Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol. 85: 1189-99.
42. Joo JD, Kim M, Horst P., Kim J, D'Agati VD, et al. (2007) Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am J Physiol Renal Physiol. 293: F1847-57.